Related Experiment Video
Updated: Jul 19, 2026

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice
Published on: January 16, 2015
miR-146a regulates emphysema formation and abnormal inflammation in the lungs of two mouse models
Hitomi Yoshikawa1, Tadashi Sato1, Kimiko Horikoshi1
1Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Abstract:
miR-146a, a microRNA (miRNA) that regulates inflammatory responses, plays an important role in many inflammatory diseases. Although an in vitro study had suggested that miR-146a is involved in abnormal inflammatory response, being a critical factor in the pathogenesis of chronic obstructive pulmonary disease (COPD), in vivo evidence of its pathogenic role in COPD remains limited. Eight-week-old male B6(FVB)-Mir146tm1.1Bal/J [miR-146a knockout (KO)] and C57BL/6J mice were intratracheally administered elastase and evaluated after 28 days or exposed to cigarette smoke (CS) and evaluated after 5 mo. miR-146a expression was significantly increased in C57BL/6J mouse lungs due to elastase administration (P = 0.027) or CS exposure (P = 0.019) compared with that in the control group. Compared with C57BL/6J mice, elastase-administered miR-146a-KO mice had lower average computed tomography (CT) values (P = 0.017) and increased lung volume-to-weight ratio (P = 0.016), mean linear intercept (P < 0.001), and destructive index (P < 0.001). Moreover, total cell (P = 0.006), macrophage (P = 0.001), neutrophil (P = 0.026), chemokine (C-X-C motif) ligand 2/macrophage inflammatory protein-2 [P = 0.045; in bronchoalveolar lavage fluid (BALF)], cyclooxygenase-2, and matrix metalloproteinase-2 levels were all increased (in the lungs). Following long-term CS exposure, miR-146a-KO mice showed a greater degree of emphysema formation in their lungs and inflammatory response in the BALF and lungs than C57BL/6J mice. Collectively, miR-146a protected against emphysema formation and the associated abnormal inflammatory response in two murine models.NEW & NOTEWORTHY This study demonstrates that miR-146a expression is upregulated in mouse lungs because of elastase- and CS-induced emphysema and that the inflammatory response by elastase or CS is enhanced in the lungs of miR-146a-KO mice than in those of control mice, resulting in the promotion of emphysema. This is the first study to evaluate the protective role of miR-146a in emphysema formation and the associated abnormal inflammatory response in different in vivo models.
Insights
MicroRNA-146a (miR-146a) protects against emphysema and inflammation in mouse models. Loss of miR-146a exacerbates lung damage and inflammatory responses in chronic obstructive pulmonary disease (COPD) models.
Area of Science:
- Pulmonary Medicine
- Molecular Biology
- Immunology
Background:
- MicroRNA-146a (miR-146a) is implicated in inflammatory diseases.
- In vitro studies suggest miR-146a's role in chronic obstructive pulmonary disease (COPD) pathogenesis.
- In vivo evidence for miR-146a's role in COPD is limited.
Purpose of the Study:
- To investigate the in vivo role of miR-146a in emphysema and associated inflammation.
- To evaluate the protective effects of miR-146a in mouse models of COPD.
Main Methods:
- Mice lacking miR-146a (miR-146a knockout) and wild-type mice were used.
- Emphysema was induced via elastase administration or cigarette smoke (CS) exposure.
- Lung structure, inflammation markers, and gene expression were analyzed.
Main Results:
- miR-146a expression increased in wild-type mice lungs following elastase or CS exposure.
- miR-146a knockout mice exhibited exacerbated emphysema and increased inflammatory responses.
- Higher levels of inflammatory cells and mediators were observed in knockout mice.
Conclusions:
- miR-146a plays a protective role against emphysema and inflammation in vivo.
- Loss of miR-146a promotes emphysema development and exacerbates inflammatory responses.
- This study provides the first in vivo evidence for miR-146a's protective role in emphysema.

